Distinguished in Asbestosis

Dr. Joseph A. Boscia

Pulmonary Medicine
Upstate Lung And Critical Care Specialists PC
151 Harold Fleming Ct, 
Spartanburg, SC 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Distinguished in Asbestosis
Upstate Lung And Critical Care Specialists PC
151 Harold Fleming Ct, 
Spartanburg, SC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Joseph Boscia is a Pulmonary Medicine provider in Spartanburg, South Carolina. Dr. Boscia is rated as a Distinguished provider by MediFind in the treatment of Asbestosis. His top areas of expertise are Lung Metastases, Chronic Obstructive Pulmonary Disease (COPD), Lung Nodules, Asbestosis, and Advanced Bronchoscopy. Dr. Boscia is currently accepting new patients.

His clinical research consists of co-authoring 9 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pulmonary Medicine
Licenses
Internal Medicine in SC
Hospital Affiliations
Spartanburg Medical Center
Cherokee Medical Center
Union Medical Center
Pelham Medical Center
Languages Spoken
English
Castilian
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Absolute Total Care South Carolina
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 18 Less Insurance Carriers -

Locations

UPSTATE LUNG AND CRITICAL CARE SPECIALISTS PC
151 Harold Fleming Ct, Spartanburg, SC 29303

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
Enrollment Status: Recruiting
Publish Date: June 25, 2025
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
Enrollment Status: Completed
Publish Date: April 11, 2024
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab
Study Phase: Phase 2/Phase 3
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Enrollment Status: Completed
Publish Date: October 16, 2023
Intervention Type: Drug
Study Drug: Ensifentrine
Study Phase: Phase 3
A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)
A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)
Enrollment Status: Completed
Publish Date: July 18, 2023
Intervention Type: Drug
Study Drugs: Gepotidacin, Nitrofurantoin
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
Enrollment Status: Completed
Publish Date: July 01, 2022
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab, LY3853113 Anti-COVID-19 Antibody, VIR-7831 Anti-COVID-19 Antibody
Study Phase: Phase 2
Blood Sample Collection in Subjects With Pulmonary Nodules or CT Suspicion of Lung Cancer or Pathologically Diagnosed Lung Cancer
Blood Sample Collection in Subjects With Pulmonary Nodules or CT Suspicion of Lung Cancer or Pathologically Diagnosed Lung Cancer
Enrollment Status: Completed
Publish Date: February 15, 2021
Intervention Type: Other
View 5 Less Clinical Trials

9 Total Publications

Age Effects in Facial Fracture Trauma: Disparities in Multisystem Injuries in Non-Fall-Related Trauma.
Age Effects in Facial Fracture Trauma: Disparities in Multisystem Injuries in Non-Fall-Related Trauma.
Journal: Cureus
Published: November 01, 2023
Similar Doctors
Distinguished in Asbestosis
Dr. Stephen H. Hand
Sleep Medicine | Intensive Care Medicine | Pulmonary Medicine
Distinguished in Asbestosis
Dr. Stephen H. Hand
Sleep Medicine | Intensive Care Medicine | Pulmonary Medicine

Anmed Health

885 Tiger Blvd, 
Clemson, SC 
 (55.3 miles away)
864-654-6800
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Stephen Hand is a Sleep Medicine specialist and an Intensive Care Medicine provider in Clemson, South Carolina. Dr. Hand is rated as a Distinguished provider by MediFind in the treatment of Asbestosis. His top areas of expertise are Lung Metastases, Chronic Obstructive Pulmonary Disease (COPD), Asbestosis, Advanced Bronchoscopy, and Gastrostomy. Dr. Hand is currently accepting new patients.

Distinguished in Asbestosis
Dr. Ravi T. Chandran
Pulmonary Medicine
Distinguished in Asbestosis
Dr. Ravi T. Chandran
Pulmonary Medicine

Prisma Health University Medical Group

210 Freeman Farm Rd, 
Duncan, SC 
 (14.6 miles away)
864-968-5123
Languages Spoken:
English, Tamil
See accepted insurances
Accepting New Patients
Offers Telehealth

Ravi Chandran is a Pulmonary Medicine provider in Duncan, South Carolina. Dr. Chandran is rated as a Distinguished provider by MediFind in the treatment of Asbestosis. His top areas of expertise are Lung Nodules, Lung Metastases, Chronic Obstructive Pulmonary Disease (COPD), Acute Interstitial Pneumonia, and Advanced Bronchoscopy. Dr. Chandran is currently accepting new patients.

Advanced in Asbestosis
Dr. Abbas H. Mansour
Pulmonary Medicine
Advanced in Asbestosis
Dr. Abbas H. Mansour
Pulmonary Medicine
201 Richard St, 
Easley, SC 
 (39.2 miles away)
864-850-0700
Languages Spoken:
English, Amharic, Arabic
See accepted insurances
Accepting New Patients

Abbas Mansour is a Pulmonary Medicine provider in Easley, South Carolina. Dr. Mansour is rated as a Distinguished provider by MediFind in the treatment of Asbestosis. His top areas of expertise are Chronic Obstructive Pulmonary Disease (COPD), Lung Metastases, Hospital-Acquired Pneumonia, Atypical Pneumonia, and Gastrostomy. Dr. Mansour is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Boscia's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 10 Advanced Conditions
    View All 38 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile